Pictet Asset Management Holding SA Purchases 1,820,944 Shares of Pfizer Inc. $PFE

Pictet Asset Management Holding SA lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 62.8% during the third quarter, HoldingsChannel reports. The firm owned 4,721,719 shares of the biopharmaceutical company’s stock after purchasing an additional 1,820,944 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Pfizer were worth $134,667,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PFE. Russell Investments Group Ltd. grew its stake in Pfizer by 15.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock valued at $132,365,000 after purchasing an additional 745,213 shares in the last quarter. Handelsbanken Fonder AB increased its holdings in Pfizer by 10.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock worth $59,295,000 after purchasing an additional 232,528 shares during the last quarter. Leuthold Group LLC purchased a new stake in Pfizer during the 2nd quarter worth approximately $4,887,000. Park National Corp OH raised its position in shares of Pfizer by 332.1% in the 2nd quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock valued at $5,829,000 after purchasing an additional 186,053 shares in the last quarter. Finally, 111 Capital acquired a new position in shares of Pfizer in the 2nd quarter valued at approximately $3,706,000. 68.36% of the stock is owned by institutional investors and hedge funds.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
• Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
• Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
• Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips

Analysts Set New Price Targets

PFE has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Cantor Fitzgerald upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. Scotiabank upped their price target on shares of Pfizer from $33.00 to $35.00 and gave the company a “sector outperform” rating in a report on Wednesday, November 4th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Finally, HSBC raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, September 10th. Six investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $30.39.

Pfizer Stock Down 0.0%

Shares of Pfizer stock opened at $29.38 on Monday. The business has a 50-day moving average price of $28.74 and a 200 day moving average price of $26.90. Pfizer Inc. has a fifty-two week low of $23.62 and a fifty-two week high of $31.44. The firm has a market cap of $167.47 billion, a P/E ratio of 41.97, a P/E/G ratio of 1.93 and a beta of 0.31. The company has a quick ratio of 1.10, a current ratio of 1.42 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. The company had revenue of $16.58 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter last year, the business posted $0.87 EPS. Pfizer’s quarterly revenue was down .4% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 3.04 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 5.9%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio is currently 245.71%.

Pfizer Profile